Home / Reports

Reports

Gulf countries discuss global harmonization of biosimilars

The regulation, approval and use of biosimilars is subject to global debate. Policies and regulations differ from country to country which can lead to confusion over biosimilars integrity. To ensure increased uptake and affordability of biosimilars, their safety and reliability needs to be assured. Worldwide, governments must adapt regulatory procedures to facilitate biosimilar market access and low prices.

Spanish pharmacists publish biosimilar position statement

The Spanish Society of Hospital Pharmacy (Sociedad Española de Farmacia Hospitalaria, SEFH) has published a position statement on the use of biosimilars [1]. The statement expresses the position of the society on the strategies to be followed concerning the processes of selecting, evaluating and implementing these types of medicines in the healthcare setting.

WHO considers cost of cancer drugs and how to increase access

The increasing prices of cancer drugs is ‘impairing the capacity of healthcare systems to provide affordable, population-wide access to cancer medicines’, according to a report issued by the World Health Organization (WHO).

International promotion and education for biosimilars

International initiatives to promote the use of biosimilars and improve their understanding is just one of the subjects investigated by a report published by the Canadian Agency for Drugs and Technologies in Health (CADTH) [1].

International prescribing incentives for biosimilars

In October 2018, the Canadian Agency for Drugs and Technologies in Health (CADTH) published a report that investigated, among other subjects, international prescribing incentives for biosimilars [1].

International supply side policies for biosimilars

A report published by the Canadian Agency for Drugs and Technologies in Health (CADTH) investigated how international supply side policies influenced the use of biosimilars [1].

International policies for interchangeability, switching and substitution of biosimilars

In its report into different international policies on the use of biosimilars, the Canadian Agency for Drugs and Technologies in Health (CADTH) investigated the issue of interchangeability, switching and substitution of biosimilars [1].

Canadian report into international policies for biosimilars

The Canadian Agency for Drugs and Technologies in Health (CADTH) has released a report that investigates different international policies on the use of biosimilars [1].

Sustainability of biosimilars in Europe

Biologicals accounted for US$277 (Euros 238) billion in sales globally in 2017 and are projected to reach US$452 (Euros 388) billion by 2022. Biosimilars are making up an increasing part of this total, with the European biosimilar market being the most mature. According to Research and Markets, the biosimilar market in Europe reached US$2 billion in 2017 and is expected to exceed US$9 billion by 2023, at a compound annual growth rate (CAGR) of 29% during 2017−2023.

Addressing uncertainty in biosimilarity

How to address uncertainty in biosimilarity was a subject discussed by Dr Patrick Lynch, Product Quality Reviewer at the US Food and Drug Administration (FDA) during the Drug Information Association’s Biosimilars Conference 2017 [1].